Capecitabine

Evidence Level: L5

Predicted Indications: 1

Capecitabine

Pharmacist Assessment Report

Capecitabine: From Colorectal and Gastric Cancer to Gastric Adenocarcinoma and Proximal Polyposis of the Stomach

One-Sentence Summary

Capecitabine is an oral fluoropyrimidine chemotherapy drug. The TxGNN model predicts it may be effective for gastric adenocarcinoma and proximal polyposis of the stomach, but the data compiled for this report contain no clinical trials and no publications that directly study this disease, so the support is model prediction only.

Quick Overview

Item	Content
Original Indication	Metastasis from malignant tumour of colon; gastric cancer (relations recorded in the knowledge graph; no approved-indication text is available in the Canadian licence records)
Predicted New Indication	Gastric adenocarcinoma and proximal polyposis of the stomach
TxGNN Prediction Score	0.9994
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 11 of 11)
Number of DINs	11 (marketed: 11)
Number of approvals	11 licences (all single-ingredient, all valid)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, capecitabine belongs to the fluoropyrimidine class of cytotoxic drugs and is widely understood to act as an oral precursor of 5-fluorouracil.

The predicted disease is a gastric adenocarcinoma syndrome. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, such as the gastric cancers already linked to the drug, not biological evidence. This is a similarity-based inference. No study in the compiled data tests capecitabine in this specific condition. Note that the predicted disease also involves proximal gastric polyposis, a hereditary or polyp-related setting that is not the same as ordinary sporadic gastric cancer.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

Eleven valid single-ingredient licences are listed. Approved-indication text, dosage form and manufacturer are not provided in the licence records, so the approved indications cannot be confirmed from the data compiled for this report. The first five licences are shown below.

DIN	Product Name
02457490	TARO-CAPECITABINE
02519879	CAPECITABINE
02426765	ACH-CAPECITABINE
02457504	TARO-CAPECITABINE
02514982	CAPECITABINE

The remaining six licences are SANDOZ CAPECITABINE (02421917, 02421925), MINT-CAPECITABINE (02508028), ACH-CAPECITABINE (02426757) and CAPECITABINE (02519887, 02514990).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (fluoropyrimidine class)
Myelosuppression Risk	Please refer to the package insert warnings and precautions. The knowledge graph lists neutropenia, thrombocytopenia, agranulocytosis and anaemia as contraindication-related conditions.
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Complete blood count, liver function, renal function (consistent with the conditions flagged below)
Handling Protection	Follow local cytotoxic drug handling regulations

Safety Considerations

Package-insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for authoritative safety information.

Contraindication-related conditions recorded in the knowledge graph (not label text): liver disease, gallbladder disease, thrombocytopenia, infectious disease, neutropenia, agranulocytosis, coronary artery disease, anaemia, macrocytic anaemia, hyperbilirubinaemia, hereditary hyperbilirubinaemia, Gilbert syndrome, impaired renal function, sudden cardiac arrest, heart conduction disease, necrotizing enterocolitis, stomatitis, and dihydropyrimidine dehydrogenase deficiency.
Drug Interactions: The interaction search returned 100 records; the first 20 are summarised here.
- Moderate: metronidazole, tinidazole.
- Minor: aluminium hydroxide, levofloxacin, magaldrate, magnesium carbonate, magnesium hydroxide, magnesium oxide.
- Unclassified severity: pantoprazole, glimepiride, doxycycline, morphine, metformin, omeprazole, lansoprazole, atropine, prednisone, simvastatin, hydrocortisone, dolasetron.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high, but no clinical trial or publication in the compiled data directly studies this disease, so the evidence level is L5 (model prediction only). Package-insert safety data are also missing, which blocks safety screening.

To proceed, the following is needed:

Search for trials and publications on capecitabine in this specific condition, including hereditary or polyposis-associated gastric cancer.
Obtain Health Canada package-insert warnings, contraindications and approved-indication text for the 11 licences.
Obtain mechanism-of-action data (for example from DrugBank) to support the mechanistic link.
Define a safety plan for the flagged conditions, especially dihydropyrimidine dehydrogenase deficiency, myelosuppression, and hepatic and renal impairment.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.